Get to know Hematologist-Oncologist Dr. Mohammed Najeeb Al Hallak, who serves patients in Detroit, Michigan.
More on YorkPedia:
- Bringing the Authentic Music of R&B the Recertified Teenager Releases New Track ‘The Groove’
- The North Carolina Music Band Apollo Craven Is Spreading Its Charm with Their Soundtracks
- Learn How to Measure Press Release Success in 11 Simple Ways
- Stay Updated about the International Music Industry with Daily Music Roll’s Music News
- Get Nostalgic with the Album ‘To Love Somebody…’ by O’Neill Fernandes
(YorkPedia Editorial):- New York City, New York Dec 14, 2021 (Issuewire.com) – A skilled hematologist-oncologist, Dr. Al Hallak is affiliated with Gastrointestinal and Neuroendocrine Oncology and the Phase I Clinical-Pharmacology Program at Karmanos Cancer Institute in Detroit, Michigan. He has profound clinical expertise in managing gastrointestinal (GI) malignancies, particularly pancreatic cancer.
Karmanos Cancer Institute specializes in providing cancer care that patients cannot get anywhere else. It is one of just 51 cancer centers throughout the country designated as a comprehensive cancer center by the National Cancer Institute (NCI). This prestigious designation means patients can access treatments exclusive to the center including clinical trials, cancer prevention programs, and multidisciplinary teams of cancer specialists.
With a broad educational background, Dr. Al Hallak graduated with his medical degree from the University of Aleppo Faculty of Medicine in Syria. After relocating to the United States, he completed his residency at the University of North Dakota and his fellowship at the Wayne State University School of Medicine.
Subsequent to his education, the doctor attained board certification in hematology, medical oncology, and internal medicine through the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.
Among his professional affiliations, he is an active member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Association of Cancer Research.
As for his academic appointment, Dr. Al Hallak serves as a Clinical Assistant Professor within the Department of Oncology at the Wayne State University School of Medicine
An enthusiastic researcher, the goal of his research is to better understand the molecular biology and microenvironment of GI cancers, discover new treatments, and prevent treatment-induced toxicities. He is able to translate a passion for improving treatment outcomes for GI cancer patients via conducting clinical trials (phase I-III), investigator-initiated and pharma-sponsored.
The doctor works through translational research to identify new biomarkers that help to individualize the treatment choice for patients and provide them with an accurate prediction of the treatment effect as well as a prognosis of their cancer. He is leading the initiative to start a postmortem rapid autopsy program for pancreatic cancer patients in Detroit.
Additionally, Dr. Al Hallak is a co-principal investigator on the Translational Pilot Trial to study the role of different microRNAs in predicting response and resistance to Gemcitabine and Nab-Paclitaxel when used as first-line therapy for metastatic or locally advanced unresectable Pancreatic cancer patients. He is also a co-leader for the Phase II Clinical Trial to study the effect of adding XPO1 inhibitor (Selinexor) to Gemcitabine as a second-line treatment for patients with metastatic or locally advanced unresectable pancreatic cancer patients after non-Gemcitabine regimen failure.
Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.
Among his most notable achievements, Dr. Al Hallak has been the recipient of the Awesome Job Award (2016), Outstanding Teacher of the Year Award (2013), and Excellence in Research Award (2011).
Learn More about Dr. Mohammad Najeeb Al Hallak:
Through his findatopdoc profile, https://www.findatopdoc.com/doctor/82660099-Mohammed-Al-Hallak-Oncologist or through Karmanos Cancer Institute, https://www.karmanos.org/karmanos/karmanos-physician-directory/al-hallak-najeeb-mohammed-9643
FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.
Your Health Contact
This article was originally published by IssueWire. Read the original article here.